About the Authors
- Ralf Duerrwald
-
Affiliation IDT Biologika GmbH, Dessau-Rosslau, Germany
- Michael Schlegel
-
Affiliation IDT Biologika GmbH, Dessau-Rosslau, Germany
- Katja Bauer
-
Affiliation Jena University Hospital, Department of Virology and Antiviral Therapy, Jena, Germany
- Théophile Vissiennon
-
Affiliation Tierpathologie Leipzig, Leipzig, Germany
- Peter Wutzler
-
Affiliation Jena University Hospital, Department of Virology and Antiviral Therapy, Jena, Germany
- Michaela Schmidtke
-
* E-mail: michaela.schmidtke@med.uni-jena.de
Affiliation Jena University Hospital, Department of Virology and Antiviral Therapy, Jena, Germany
Competing Interests
The authors Ralf Duerrwald and Michael Schlegel are employed at the Research and Development department of IDT Biologika GmbH. The investigations reported in this manuscript were of scientific interest. The investigations could have been done by other institutions in a similar manner because the vaccine and drug used in the experiments are commercially available. The publication does not touch patents, consultancy or products in development. The vaccine administered is a marketed product of IDT Biologika GmbH. It was used because no other trivalent swine influenza vaccine containing H1N2 is licensed in Europe. This does not alter the authors' adherence to all PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: RD M. Schlegel PW M. Schmidtke. Performed the experiments: RD M. Schlegel KB TV. Analyzed the data: RD KB TV M. Schmidtke. Contributed reagents/materials/analysis tools: RD TV PW M. Schmidtke. Wrote the paper: RD M. Schmidtke.